Aggregating Technology and Expanding Markets… Daewoong Unleashes Digital Health 'Platform' Strategy

Leveraging 'ThynC' success capabilities as a platform for innovative technology partners,accelerating growth into 'All New ThynC,' and expanding the market to remote work... Pilot projects in the first half of the year

by Jo Hu-hyeon

02.24.2026 11:57

Seers Technology CEO Lee Young-shin, ikoob CEO Cho Jae-hyung, Daewoong Pharmaceutical Executive Vice President Park Hyung-chul, Skylab Labs Senior Vice President Park Sun-hee, and Puzzle AI CEO Kim Yong-sik.

Photo by Cho Hoo-hyun

[Medipana News = Reporter Jo Hoo-hyun] Daewoong Pharmaceutical is fully launching its role as a 'platform' leading digital healthcare. The strategy involves consolidating its position in the digital healthcare market by gathering innovative technologies centered on the smart bed monitoring system 'thynC,' while simultaneously pioneering and expanding into the market outside of hospitals.

Park Hyung-cheol, Head of ETC Marketing at Daewoong Pharmaceutical, shared a roadmap for achieving the vision of a '24-hour national health monitoring system' at a press conference announcing the digital healthcare vision on the 23rd.

According to this, Daewoong Pharmaceutical will fully launch its role as a digital healthcare platform starting this year. While previously limited to collaborating with individual companies, the company now plans to function as a platform that aggregates technologies and creates synergy.

"The greatest significance of this All New ThynC Partnership is that innovative technologies accumulated in each field have begun to operate as a single system in the medical field," said Director Park. "We will not simply introduce individual technologies, but rather organically connect different data and solutions on a single platform and play a role in implementing them in a form that medical professionals can utilize in actual clinical practice."

Performance underlies the ability to function as a digital healthcare platform. As Daewoong Pharmaceutical began full-scale supply of Seers Technology's 'ThynC' last year, it increased the number of beds equipped with the system from 840 in 2024 to 12,000 by the end of last year. As of the 9th, it recorded over 15,000 beds, an increase of another 3,000 beds, demonstrating a steep expansion trend.

As such, the capability to supply and expand digital healthcare technology to hospitals acts as a factor in technology development companies choosing the Daewoong Pharmaceutical platform.

"I have been active as a researcher in this field for over 20 years, but creating something and making it used are completely different things. It is incredibly difficult to explain well-made technology in the hospital setting and ensure it can be used," said Jo Jae-hyung, CEO of ikoob. "Daewoong is doing this work well. The ability to introduce and connect the technologies and solutions we create to the field is a tremendous strength and something that not just anyone can do."

This year, the company is accelerating the growth of digital healthcare by introducing 'All New ThynC,' which integrates and enhances partner technologies into its flagship product, ThynC. All New ThynC integrates with ikoob's 'CGM LIVE,' Skylab's 'CART ON,' and Puzzle AI's 'CL NOTE.'

CGM LIVE is a multi-patient blood glucose monitoring system. It minimizes the burden of blood sampling for patients and medical staff through continuous blood glucose measurement, and the system sends alarms to enable medical staff to respond when abnormal blood glucose levels occur. When integrated with ThynC, it is expected to provide indicators for determining the causes of pulse rate fluctuations through blood glucose monitoring in hospitalized patients.

"It is extremely important to monitor blood sugar levels along with other indicators. This is because it allows us to understand pulse changes based on blood sugar and precisely identify problems," said Jo Jae-hyung, CEO of ikoob. "We will continue to develop this into a system that enables medical professionals to view and analyze more data at a glance."

CART ON is a ring-type capless blood pressure monitor that enhances convenience and compliance compared to 24-hour ambulatory blood pressure monitoring. It allows for continuous monitoring of blood pressure trends through hourly data synchronization. It is explained that integration with ThynC enables the automation of blood pressure measurement tasks for medical staff and minimizes data errors.

Park Sun-hee, a senior executive at Skylabs, said, "Measuring blood pressure took up a large part of a nurse's job, and there was a possibility of errors in the records," adding, "We expect that automating this will allow nurses to return to their basic nursing duties."

CL NOTE is a technology that reduces the burden of writing medical records through real-time medical recording and summarization based on AI voice recognition. It applies a method that reduces omissions and errors through real-time voice nursing records. When integrated with ThynC, it is expected that scalability will be significantly expanded as all clinical symptoms, including real-time patient symptoms, physician treatment details, and nurse care details, will be linked within a single platform.

Kim Yong-sik, CEO of Puzzle AI, said, "In the medical system, the final destination of healthcare technology outcomes is records," adding, "The fact that CL NOTE is integrated with ThynC means that all data, from vital signs to doctor treatments and nurse care, is linked to the platform. This means that data accuracy is secured and scalability is greatly expanded."

ThynC, the central platform, will continue to be advanced even after this technology integration. It will expand the range of vital signs that need to be monitored in inpatient wards, such as electromyography, expiratory volume, and brainwaves, as well as expand AI algorithms for predicting the severity of illness.

Lee Young-shin, CEO of Seers Technology, said, "Going forward, the development of ThynC technology will be a process of expanding the scope of monitoring and increasing the target population," adding, "We will expand the system into a full-cycle platform ranging from monitoring of hospitalized patients to patients discharged from home, home rehabilitation, home hospitalization, and pre-hospital monitoring of emergency patients."

The company's stated goal for this year is 100,000 beds and 300 billion won in revenue. This target is even higher than the sales of 'Nabota,' the flagship botulinum toxin product that drove the company's performance last year, recording 228.9 billion won as a single item.

The company will continue to strengthen its role as a digital healthcare platform. First, it will continue to expand technology in All New ThynC.

Director Park stated, "If we have the opportunity to explain Daewoong Pharmaceutical's digital healthcare solutions again around this time next year, we are preparing a solution to measure sarcopenia on the ThynC platform and technology to measure lung function in hospital wards," adding, "I think next year's meeting will be even more enriching."

In the mid-to-long term, efforts are also being made to expand the market beyond hospital beds to home-based care by utilizing digital healthcare platforms. The plan is to explore the potential for market expansion beyond hospitals to home-based care, with the goal of establishing a 24-hour national health monitoring system.

Park Hyung-cheol, Head of ETC Marketing at Daewoong Pharmaceutical, stated, "The vision for 24-hour national health monitoring is scheduled to proceed as a pilot project within the first half of this year," adding, "I believe this year will be the inaugural year of the project."

Source : Medipana News(https://www.medipana.com)